Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Agenix Discloses Plans for Clinical Trial of Hepatitis B Drug

publication date: Jun 8, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Agenix released a long-lead schedule for China approval of its new treatment for hepatitis B, AGX-1009. If everything goes according to plan, the company will apply in Q2 of 2012 to begin clinical trials of the drug. The trials themselves could start as early as late 2012. Agenix is developing the drug in partnership with the Institute of Medicinal Biotechnology (IMB), located in Beijing, a division of the Chinese Academy of Medical Sciences. More details....

Stock Symbol: (ASX: AGX)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners